Peptide therapy TikTok claims: what the science actually supports

What did @paulbakhtiar actually say?

Bakhtiar describes himself as someone who builds peptide programs for wellness centers and "meds balls" (likely medspa or medball facilities). His pitch is a "four-part system" covering business strategy, training, education, supply, and marketing. The goal, in his words, is to help businesses build a "six-figure revenue system" that is "turn key."

To be clear: this video is not really about peptide science. It is a B2B sales pitch aimed at clinic owners and wellness entrepreneurs. Bakhtiar is not claiming clinical outcomes for patients. He is claiming he can make someone money. That distinction matters a lot for how we evaluate what he said.

There are no therapeutic claims here, no dosing recommendations, no promises that BPC-157 heals tendons or that CJC-1295 reverses aging. That absence is notable, and not in a bad way.

Does the science back this up?

There is no science to evaluate here in the traditional sense. This is a business development pitch, not a clinical claim. What we can assess is whether the framing around "peptide integration" for wellness centers reflects a real and regulated industry.

Peptide therapy is genuinely expanding in outpatient and concierge medicine settings. A 2022 review by Lau and colleagues in Biomolecules noted that bioactive peptides represent a growing class of therapeutic candidates, though most with limited Phase III data in humans. Compounded peptides, the type typically used in wellness clinics, operate under 503A and 503B pharmacy frameworks in the U.S., which are subject to FDA oversight but distinct from approved drug pathways.

The business model Bakhtiar describes, supplying clinics with protocols and product sourcing, exists and is real. Whether it is ethical and compliant depends entirely on who is prescribing, what is being compounded, and whether patients are being properly evaluated. None of that is addressed in this video.

What did they get wrong (or right)?

Bakhtiar did not make false clinical claims, which is more than can be said for most peptide content on TikTok. Credit where it is due.

What is missing, and this is a real problem, is any acknowledgment of the regulatory complexity involved. Wellness centers adding peptide programs are stepping into a space where the FDA has been actively cracking down. In 2023 and 2024, the FDA placed several peptides, including BPC-157 and TB-500, on its list of substances that cannot be compounded under federal law. Any clinic that "turns key" into a peptide program without understanding that regulatory environment could face serious legal exposure.

Bakhtiar's framing of this as a straightforward revenue play also glosses over the liability side. Clinics dispensing compounded peptides without adequate prescriber oversight, patient screening, or informed consent processes are not just legally vulnerable. They are potentially putting patients at risk. A "six-figure revenue system" built on shaky compliance is not a business model. It is a lawsuit waiting to happen.

What should you actually know?

If you are a clinic owner or wellness entrepreneur watching this video, the actual question you should be asking is not whether peptides can generate revenue. The question is whether you can offer them legally and safely in your state and under current FDA guidance.

As of 2024, several commonly promoted peptides have been removed from the FDA's 503A bulks list, meaning licensed compounding pharmacies can no longer legally produce them for patient-specific prescriptions. That includes BPC-157 and TB-500, two of the most hyped peptides in the wellness space. Any vendor promising a "turn key" peptide supply program should be able to tell you exactly which peptides remain compoundable and under what conditions. If they cannot, that is a red flag.

The promise of a seamless, done-for-you system also raises questions about who is actually practicing medicine in that model. Peptide therapy requires a licensed prescriber, individualized assessment, and ongoing monitoring. A business strategy package does not replace that. Clinics that treat it as a product to sell rather than a clinical service to provide are operating in dangerous territory, for patients and for themselves.